Glaxo's HIV Drug May Be Linked To Heart Attack Risk -Study
After analyzing data from a study investigating six HIV medicines, researchers at the Rigshospitalet and University of Copenhagen, Denmark, found that recent use of Ziagen was linked to a twofold increase in the risk of heart attack.
Ziagen's active ingredient, abacavir, is also used in
Another less commonly used HIV treatment,
No links were found between the rate of heart attack and cumulative or recent
use of the other treatments: zidovudine and stavudine, which are available
The researchers suggested the increased incidence of heart attack from Ziagen and Videx could be attributed to a cardiovascular inflammatory response to the drugs, but pointed out more research is needed in this area.
In a letter published alongside the article,
In a linked comment to both the article and
They said that that although findings from observational studies should not lead to changes in clinical practice, the significantly increased risk of heart attack cannot be ignored.
"Alternatives to abacavir and didanosine in high-risk patients should be considered," they added.
Although Ziagen is one of
Journal web site: www.thelancet.com
(END) Dow Jones Newswires